Pieris Pharmaceuticals GmbH   Report issue

For profit Phase 1 Phase 2
Founded: Boston MA United States (2001)

Organization Overview

First Clinical Trial
2010
NCT01141257
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Pieris Australia Pty Ltd | Pieris Pharmaceuticals | Pieris Pharmaceuticals GmbH | Pieris Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

prs-080 (3 trials)

prs-344 (1 trial)

Drugs in Phase 1 Trials (4)

angiocal (1 trial)

atezolizumab (tecentriq) (1 trial)

prs-060 (2 trials)

prs-343 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 1)

Kidney Diseases (Phase 2)

Neoplasms (Phase 1)

Renal Insufficiency, Chronic (Phase 2)

Respiratory Aspiration (Phase 1)

Stomach Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 6